iSpecimen Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated revenue of $106,592 for the third quarter, a stark decline of approximately 96% compared to $2,661,936 in the same period last year. For the nine months ended September 30, 2025, total revenue was $1,877,237, down 76% from $7,815,608 in the prior year. This decline was attributed primarily to a drastic reduction in specimen count, which fell from 19,620 to 5,122 specimens, reflecting a shift in revenue recognition practices that now only account for delivered specimens.
Operating expenses also decreased, totaling $2,936,814 for the third quarter, down 33% from $4,367,340 in the previous year. Notably, costs associated with revenue fell by 87% to $204,593, while technology expenses decreased by 27% to $551,104. However, sales and marketing expenses rose by 81% to $1,140,902, indicating increased investment in these areas despite overall cost-cutting measures. The net loss for the quarter was $2,780,648, a 93% increase from the loss of $1,439,853 reported in the same quarter of 2024.
In terms of strategic developments, iSpecimen has been actively restructuring its operations to improve efficiency and reduce costs. The company has implemented a workforce reduction that has led to a significant decrease in monthly compensation and technology costs. As of September 30, 2025, the company had cash and cash equivalents of $2,782,758, an increase of 48% from $1,878,408 at the end of 2024. However, the company continues to face a working capital deficit of $2,096,503 and an accumulated deficit of $77,348,904.
The company has also engaged in various financing activities, including a public offering that raised approximately $3,999,574 in gross proceeds. This was part of a broader strategy to secure additional working capital amid ongoing operational challenges. iSpecimen's management has expressed concerns about the company's ability to continue as a going concern, emphasizing the need for additional capital and improved revenue generation to sustain operations.
Looking ahead, iSpecimen plans to focus on enhancing its sales strategies and operational efficiencies. The company aims to leverage its technology platform to better connect researchers with biospecimens while continuing to streamline its supplier network. However, management acknowledges that external market conditions and the ongoing economic environment may impact its ability to achieve these goals.
About iSpecimen Inc.
iSpecimen Inc. operates a technology-driven marketplace connecting life science researchers with human biospecimens and associated data from healthcare providers worldwide. Its platform streamlines biospecimen procurement, offering access to diverse specimen types and extensive healthcare data, supporting research in diagnostics, therapeutics, and precision medicine. The company facilitates compliant, efficient transactions between researchers and biospecimen providers, enabling accelerated medical discovery and development.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.